# Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

> **NCT06004674** · PHASE2 · RECRUITING · sponsor: **Endeavor Health** · enrollment: 20 (estimated)

## Conditions studied

- Adverse Pregnancy Outcome

## Interventions

- **DRUG:** Lovenox 40mg

## Key facts

- **NCT ID:** NCT06004674
- **Lead sponsor:** Endeavor Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-26
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06004674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06004674, "Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06004674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*